WE CAN KICK CANCER'S BUTT
Our strategic partnership with Cure Search allows us to drive critical collaborations to accelerate the pace of pediatric drug development.
With the unmatched expert leadership of their Scientific and Industry Councils, Cure Search identifies and funds only the most innovative research with the potential to move quickly into the clinic and marketplace, reaching children now – not 10-20 years from now.
AN URGENT UNMET NEED: CANCER IS THE #1 DISEASE KILLER IN CHILDREN
Fact:Since 1980, only 4 cancer drugs have been developed an approved specifically for children
Fact: Despite improved outcomes for the most common form of childhood cancer, many other survival rates remain less than 50%, and in some cases, less than 1%
Fact: As many as 85% of children who survive cancer develop one or more chronic health conditions including secondary cancers|
Together, We Are Making an Impact
It is our goal to protect the future of children diagnosed with cancer by delivering better, less-toxic treatments. This can’t happen without your help. We thank you for your support in the fight against children’s cancer.
30 New Drugs In Pre-Clinical Testing
Using models developed from the tumors of pediatric cancer patients or made through genetic manipulation of cells, CureSearch investigators are testing novel treatment strategies in their labs. These innovative therapeutics have been designed to address tumors of high unmet need, with low survival or insufficient safe treatment options. If these potential therapies successfully reduce tumor burden with minimal side-effects in the tumor models systems, these treatment options will quickly move out of the lab and into clinical trials.
300+ Potential New Drug Targets
CureSearch investigators have assed biopsies, cell lines, and animal models derived from patients with pediatric cancers including ALL, AML, medulloblastoma, ependymoma, choroid plexus carcinoma, rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, and Wilms tumor. This work has led to the identification of over 300 new potential drug targets that are now moving to preclinical evaluation